Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

OXBRYTA

VOXELOTOR

Standard Dose
300MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview OXBRYTA is listed in Drugs@FDA under application 216157 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient VOXELOTOR Form and strength TABLET, FOR SUSPENSION;ORAL - 300MG Sponsor GLOBAL BLOOD THERAPS Submission history Latest submission status date: 2023-08-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview OXBRYTA is listed in Drugs@FDA under application 216157 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient VOXELOTOR Form and strength TABLET, FOR SUSPENSION;ORAL - 300MG Sponsor GLOBAL BLOOD THERAPS Submission history Latest submission status date: 2023-08-18 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.